Skip to main content
. Author manuscript; available in PMC: 2018 Feb 1.
Published in final edited form as: Clin Exp Allergy. 2017 Jan 11;47(2):224–235. doi: 10.1111/cea.12866

Figure 3.

Figure 3

IL-13-induced eotaxin release from human airway smooth muscle (ASM) cells requires ROCK2. Human ASM cells from 2 different donors were grown to confluency, serum deprived and insulin and transferrin supplemented for 24 h, and then treated with increasing concentrations of either (A) the ROCK2 specific inhibitor, SR3677, or (B) the pan ROCK inhibitor, Y-27632, for 30 minutes before challenge with IL-13 (100 ng/ml) for 24 hrs. Eotaxin in the supernatant was measured by ELISA and is expressed as a % of the eotaxin measured in the IL-13 treated cells that did not receive ROCK inhibitor. Results are mean ± SEM of n=4-8 per treatment. *p<0.05 vs untreated cells; # p<0.05 vs IL-13 only treated cells. The ELISA assay was conducted at least in duplicate for each donor and at each concentration. Data were normalized to eotaxin levels of IL-13 treated cells that did not receive ROCK inhibitors.